Innovating Works

UNIVERSITAETSKLINIKUM FRANKFURT

Desconocido
MIRACLE: Integrated multi angle research and training network to eradicate leukemia minimal residual disease An estimated 300,000 new cases of leukemia are diagnosed each year globally. The most common form of acute leukemia is acute myeloid leukemi...
2024-06-28 - 2028-11-30 | Financiado
ERICA: European Rare dIsease research Coordination and support Action KLINIKUM DER JOHANN WOLFGANG VON GOETHE UNIVERSITAET participó en un H2020: H2020-SC1-BHC-2018-2020 Rare diseases are defined as diseases that affect not more than 1 person per 2000 in the European population. While individual rare diseases...
2021-01-15 - 2025-02-28 | Financiado
EULAT Eradicate GBC: Establishment and Exploitation of a European Latin American Research Consortium towards Eradication... KLINIKUM DER JOHANN WOLFGANG VON GOETHE UNIVERSITAET participó en un H2020: H2020-SC1-BHC-2018-2020 Gallbladder cancer (GBC) is a neglected disease with huge potential for prevention. This project aims at significantly improving the accurac...
2019-08-21 - 2025-11-30 | Financiado
EJP RD: European Joint Programme on Rare Diseases KLINIKUM DER JOHANN WOLFGANG VON GOETHE UNIVERSITAET participó en un H2020: H2020-SC1-BHC-2018-2020 As recognized by the Council Recommendation 2009/C 151/02, rare diseases (RD) are a prime example of a research area that can strongly profi...
2018-12-13 - 2024-08-31 | Financiado
ACADEMIC GMP: The impact of Regulation EC No 1394 2007 on the development of Advanced Therapy Medicinal Products... KLINIKUM DER JOHANN WOLFGANG VON GOETHE UNIVERSITAET participó en un FP7: Advanced Therapy Medicinal Products (ATMPs) are medicinal products for human use, based on gene therapy, somatic cell therapy or tissue engi...
Financiado
APO-SYS: Apoptosis systems biology applied to cancer and AIDS. An integrated approach of experimental biology... KLINIKUM DER JOHANN WOLFGANG VON GOETHE UNIVERSITAET participó en un FP7: A Europe-wide consortium of experimental biologists, biomathematicians, biostatisticians, computer scientists and clinical scientists will t...
Financiado
BAMI: The effect of intracoronary reinfusion of bone marrow derived mononuclear cells BM MNC on all caus... KLINIKUM DER JOHANN WOLFGANG VON GOETHE UNIVERSITAET participó en un FP7: Although the long term prognosis of patients suffering acute myocardial infarction (AMI) has improved since the introduction of reperfusion...
Financiado
JUSTBRAIN: Blood brain barrier junctions as targets for paracellular drug delivery to the brain KLINIKUM DER JOHANN WOLFGANG VON GOETHE UNIVERSITAET participó en un FP7: To maintain homeostasis of the central nervous system (CNS) the blood-brain barrier (BBB) prevents the free transcellular passage of hydroph...
Financiado
NET4CGD: Gene Therapy for X linked Chronic Granulomatous Disease CGD KLINIKUM DER JOHANN WOLFGANG VON GOETHE UNIVERSITAET participó en un FP7: This project is focused on the clinical development of a new orphan drug that can rapidly become a new treatment option for patients with th...
Financiado
APO-DECIDE: Apoptosis Modelling for Treatment Decisions in Colorectal Cancer KLINIKUM DER JOHANN WOLFGANG VON GOETHE UNIVERSITAET participó en un FP7: "With the arrival of new colorectal cancer (CRC) therapeutics targeting specific cell signalling pathways, such as anti-EGFR therapy, person...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.